Stock of the Day

August 5, 2019

IDEXX Laboratories (IDXX)

$559.97
+$12.79 (+2.3%)
Market Cap: $44.14B

About IDEXX Laboratories

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDEXX Laboratories Bull Case

Here are some ways that investors could benefit from investing in IDEXX Laboratories, Inc.:

  • IDEXX Laboratories, Inc. recently demonstrated strong fundamental performance by beating analyst expectations in its most recent earnings report, posting earnings per share of $4.27 against a consensus estimate of $3.94, which indicates the company is generating higher profits than the market anticipated.
  • The company has shown consistent revenue growth, with the most recent quarter seeing revenue increase by 9.7% on a year-over-year basis, suggesting that demand for its veterinary diagnostic products and services remains robust and is expanding.
  • IDEXX Laboratories, Inc. currently trades at a stock price of $529.01, which is significantly below the average analyst price target of $747.00, implying that the stock may be undervalued relative to the long-term growth potential projected by financial experts.
  • The company maintains a strong financial position with a low debt-to-equity ratio of 0.19, meaning it relies less on borrowed money to fund its operations, which provides a safety cushion against economic downturns and allows for greater financial flexibility.
  • IDEXX Laboratories, Inc. has a high return on equity of 71.96%, a metric that measures how effectively the company uses shareholder capital to generate profits, indicating that management is highly efficient at turning invested money into earnings.

IDEXX Laboratories Bear Case

Investors should be bearish about investing in IDEXX Laboratories, Inc. for these reasons:

  • The stock is trading at a price-to-earnings ratio of 37.20, which is considered elevated, meaning investors are paying a premium for each dollar of earnings, and this high valuation leaves little room for error if future growth slows down.
  • Recent insider activity has been predominantly negative, with multiple executives and directors, including the CEO and EVPs, selling significant blocks of shares in early 2026, which can signal a lack of confidence in the stock's near-term upside from those closest to the company.
  • IDEXX Laboratories, Inc. has a beta of 1.55, a measure of volatility that indicates the stock is 55% more volatile than the overall market, meaning it is likely to experience larger price swings in both directions compared to the broader economy.
  • The company's current stock price of $529.01 is well below its 52-week high of $769.98, suggesting that the stock has undergone a significant correction and may be facing headwinds or market skepticism that has not yet been resolved.
  • Some institutional investors, such as First Citizens Bank & Trust Co., have recently decreased their stakes in the company, which may indicate that large financial players are re-evaluating their exposure to the stock or seeking to reduce risk in their portfolios.
← Previous Stock of the DayNext Stock of the Day →

Recent News